Indications › Obesity & overweight › tirzepatide

tirzepatide in obesity & overweight

tirzepatide is approved in the US for obesity & overweight, and has 84 trials on file here in this condition. 52 of them are phase 3 or later. The next scheduled result is 2026-11.

84 registered trials study tirzepatide (Mounjaro, Zepbound) in obesity & overweight, 60 of them still active and 18 in phase 3. The next is due to report 2026-11.

Trials on file: 84
Active: 60
Active phase 3: 18
Participants in active trials: 35,796
Sponsors: 49
Scheduled readouts: 24

Scheduled to report

Dates are filed by the sponsor and move often. Each links to its own record and change history.

Est. completion	Trial	Phase	Participants
2026-11	A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity NCT06662383 · Eli Lilly and Company	P3	800
2026-11	A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight NCT06962280 · Eli Lilly and Company	P3	465
2026-11	A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight NCT06914895 · Eli Lilly and Company	P3	905
2026-12-31	TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation NCT06802081 · The Cleveland Clinic	P2	100
2027-02-04	Efficacy and Safety of HDM1005 Compared to Tirzepatide in Obese Adults Without Diabetes NCT07521631 · Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.	P2	372
2027-02-14	Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1) NCT07481747 · Hudson Biotech	P3	2,539
2027-03-20	The Effects of Tirzepatide in People With Overweight/Obesity and Coronary Artery Disease NCT06606821 · Tina Vilsbøll	P4	124
2027-05	Subcutaneous Tirzepatide Once-weekly in Patients With Obesity and Knee Osteoarthritis (STOP KNEE-OA) NCT06191848 · University of Melbourne	P4	352
2027-05-31	Resistance Training to Prevent Muscle Loss During Treatment With Tirzepatide NCT07777575 · Technical University of Munich	P4	150
2027-07	A Study of Tirzepatide (LY3298176) in Adult Participants in India With Either Type 2 Diabetes Mellitus or Obesity NCT07438444 · Eli Lilly and Company	P4	344
2027-08	A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA) NCT06864026 · Eli Lilly and Company	P4	200
2027-08-10	Efficacy, Safety, and Tolerability of Tirzepatide in Real-World Conditions in Paraguay. NCT07588438 · Las Rías Medical Center	P4	160
2027-08-15	Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese NCT06732245 · Biomed Industries, Inc.	P2	224
2027-09	A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight NCT06143956 · Eli Lilly and Company	P2	1,481
2027-10	A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity NCT05556512 · Eli Lilly and Company	P3	15,374
2027-10	A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2) NCT06439277 · Eli Lilly and Company	P3	300
2027-10-31	AI-Assisted Lifestyle Intervention Versus Tirzepatide for Obesity and Newly Diagnosed Type 2 Diabetes NCT07697391 · The First Affiliated Hospital of Anhui Medical University	P4	285
2027-12-01	Efficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorder NCT06847399 · Johns Hopkins University	P2	105
2028-04	Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study NCT06937086 · Eli Lilly and Company	P3	350
2028-05	Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight NCT06937099 · Eli Lilly and Company	P3	290
2028-05	A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO) NCT06857942 · Eli Lilly and Company	P4	200
2028-09-30	AI-assisted Multi-domain Lifestyle Versus Tirzepatide for Weight Loss Maintenance in Adults With Type 2 Diabetes (AIM-MAINTAIN) NCT07555730 · Huazhong University of Science and Technology	P4	400
2028-12	A Clincial Study Testing Tirzepatide on Reproductive Function and Metabolic Health in Women With PCOS Who Are Overweight or Obese NCT07326111 · University of Bonn	P4	198
2028-12-01	Tirzepatide Versus Positive Airway Pressure for the Treatment of Obstructive Sleep Apnoea: A Randomised Comparative Effectiveness Trial NCT07846865 · Woolcock Institute of Medical Research	P2/P3	256

All trials on file

Every registered trial of tirzepatide grouped under obesity & overweight, largest first. Grouping follows the registry’s own condition wording.

Trial	Status	Phase	Sponsor
A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity NCT05556512	Active, not recruiting	P3	Eli Lilly and Company
A Study of Tirzepatide (LY3298176) Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes (SURMOUNT-REAL UK) NCT07247084	Recruiting	P4	Eli Lilly and Company
Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1) NCT07481747	Recruiting	P3	Hudson Biotech
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight NCT04184622	Completed	P3	Eli Lilly and Company
A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes NCT07881432	Not yet recruiting	P3	Eli Lilly and Company
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight NCT06143956	Recruiting	P2	Eli Lilly and Company
A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes NCT07881458	Not yet recruiting	P3	Eli Lilly and Company
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight NCT04657003	Completed	P3	Eli Lilly and Company
A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight NCT06914895	Active, not recruiting	P3	Eli Lilly and Company
A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity NCT06662383	Active, not recruiting	P3	Eli Lilly and Company
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight Loss NCT04660643	Completed	P3	Eli Lilly and Company
A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial NCT04847557	Completed	P3	Eli Lilly and Company
Effect of Tirzepatide on Recurrence of Atrial Fibrillation After Catheter Ablation in Obese Patients NCT07715929	Not yet recruiting	P4	Yunlong Wang
A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program NCT04657016	Completed	P3	Eli Lilly and Company
Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea NCT05412004	Completed	P3	Eli Lilly and Company
A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight NCT06962280	Active, not recruiting	P3	Eli Lilly and Company
A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities NCT06047548	Completed	P3	Eli Lilly and Company
Efficacy and Safety of Tirzepatide for Weight Management NCT06918405	Active, not recruiting	P3	Chittagong Medical College
A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity NCT06037252	Active, not recruiting	P2	Eli Lilly and Company
AI-assisted Multi-domain Lifestyle Versus Tirzepatide for Weight Loss Maintenance in Adults With Type 2 Diabetes (AIM-MAINTAIN) NCT07555730	Not yet recruiting	P4	Huazhong University of Science and Technology
A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity NCT06373146	Completed	P2	Eli Lilly and Company
Efficacy and Safety of HDM1005 Compared to Tirzepatide in Obese Adults Without Diabetes NCT07521631	Recruiting	P2	Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes NCT06603571	Completed	P2	Eli Lilly and Company
A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Help People With Excess Body Weight Lose Weight NCT06326060	Completed	P2	Novo Nordisk A/S
Subcutaneous Tirzepatide Once-weekly in Patients With Obesity and Knee Osteoarthritis (STOP KNEE-OA) NCT06191848	Active, not recruiting	P4	University of Melbourne
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study NCT06937086	Recruiting	P3	Eli Lilly and Company
A Study of Tirzepatide (LY3298176) in Adult Participants in India With Either Type 2 Diabetes Mellitus or Obesity NCT07438444	Active, not recruiting	P4	Eli Lilly and Company
Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight Participants NCT06737042	Completed	P2	Gan and Lee Pharmaceuticals, USA
A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2) NCT06439277	Recruiting	P3	Eli Lilly and Company
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight NCT06937099	Recruiting	P3	Eli Lilly and Company
AI-Assisted Lifestyle Intervention Versus Tirzepatide for Obesity and Newly Diagnosed Type 2 Diabetes NCT07697391	Not yet recruiting	P4	The First Affiliated Hospital of Anhui Medical University
A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity NCT06965413	Active, not recruiting	P2	Hoffmann-La Roche
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight NCT06588283	Completed	P3	Eli Lilly and Company
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight NCT06588296	Completed	P3	Eli Lilly and Company
A Study of Tirzepatide (LY3298176) in Participants With Obesity Disease NCT04844918	Completed	P3	Eli Lilly and Company
Tirzepatide Versus Positive Airway Pressure for the Treatment of Obstructive Sleep Apnoea: A Randomised Comparative Effectiveness Trial NCT07846865	Not yet recruiting	P2/P3	Woolcock Institute of Medical Research
A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight NCT06643728	Active, not recruiting	P2	Eli Lilly and Company
Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese NCT06732245	Not yet recruiting	P2	Biomed Industries, Inc.
A Study of Tirzepatide (LY3298176) in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Overweight (SURMOUNT-CN) NCT05024032	Completed	P3	Eli Lilly and Company
Efficacy and Safety of Oral Azelaprag Plus Once Weekly Tirzepatide Compared with Tirzepatide Alone in Participants with Obesity Aged 55 Years and Over NCT06515418	Terminated	P2	BioAge Labs, Inc.
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO) NCT06857942	Recruiting	P4	Eli Lilly and Company
A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA) NCT06864026	Active, not recruiting	P4	Eli Lilly and Company
A Clincial Study Testing Tirzepatide on Reproductive Function and Metabolic Health in Women With PCOS Who Are Overweight or Obese NCT07326111	Recruiting	P4	University of Bonn
Efficacy, Safety, and Tolerability of Tirzepatide in Real-World Conditions in Paraguay. NCT07588438	Recruiting	P4	Las Rías Medical Center
A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities NCT06075667	Active, not recruiting	P3	Eli Lilly and Company
Resistance Training to Prevent Muscle Loss During Treatment With Tirzepatide NCT07777575	Recruiting	P4	Technical University of Munich
Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS) NCT07817875	Recruiting	P3	Eli Lilly and Company
A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes NCT05536804	Completed	P2	Eli Lilly and Company
Glucagon-Like Peptide-1 Receptor Agonist in ADPKD NCT06582875	Recruiting	P2	University of Colorado, Denver
The Effects of Tirzepatide in People With Overweight/Obesity and Coronary Artery Disease NCT06606821	Recruiting	P4	Tina Vilsbøll
A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of Obesity NCT06565611	Active, not recruiting	P2	Palatin Technologies, Inc
Efficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorder NCT06847399	Recruiting	P2	Johns Hopkins University
Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or Obese NCT06445075	Completed	P2	Scholar Rock, Inc.
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation NCT06802081	Recruiting	P2	The Cleveland Clinic
A Study of BGM0504 in Participants With Obesity NCT06911203	Completed	P2	BrightGene Bio-Medical Technology Co., Ltd.
Efficacy of Tirzepatide for Weight Management in Patients With Suboptimal Weight Loss After Bariatric Surgery: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial NCT07829198	Not yet recruiting	P3	Universidade do Porto
Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity NCT05912621	Recruiting	P2	Stanford University
Effect of Tirzepatide and Bimagrumab on Body Composition, Insulin Sensitivity, and Bone in Adults With Obesity NCT05933499	Recruiting	P2	Massachusetts General Hospital
Evaluation of the Efficacy and Safety of Tirzepatide, a Dual GLP-1/GIP Agonist, on Functional Capacity in Reduced Ejection Fraction Heart Failure Patients With Obesity NCT07738276	Not yet recruiting	P3	Shahid Beheshti University of Medical Sciences
Tirzepatide's Effects on Epigenetic Aging and Metabolic Restoration in Virally Suppressed People With HIV NCT07707778	Enrolling by invitation	P4	National Taiwan University Clinical Trial Center

See the full record for tirzepatide, or every molecule being studied in obesity & overweight. These are registered trials, nothing more. Most drugs tested in a new condition never get approved for it, and plenty of these will report nothing useful.